DR info

臨床試験数 : 43 / 薬物数 : 52 - (DrugBank : 15) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 26

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

18 FDG
   National Institute of Neurological Disorders and Stroke (NINDS)
      1992   -   NCT00001325   United States;
ACTH
   All India Institute of Medical Sciences, New Delhi
      2022   Phase 2/Phase 3   NCT05279118   India;
   Wayne State University
      2013   Phase 4   NCT02092883   United States;
AMZ002
   Amzell B.V.
      -   Phase 3   EUCTR2021-003015-26-FR   France;Germany;Poland;Spain;United States;
Adrenocorticotropin hormone
   Ann & Robert H Lurie Children's Hospital of Chicago
      2011   -   NCT01367964   United States;
Cannabidiol (CBD)
   GW Research Ltd
      -   Phase 3   EUCTR2015-004904-50-PL   Hungary;Italy;Poland;United Kingdom;United States;
Cannabidiol Oral Solution
   Benuvia Therapeutics Inc.
      2018   Phase 3   NCT03421496   United States;
Combination therapy with vigabatrin and prednisolone
   Kullasate Sakpichaisakul
      2020   -   NCT04302116   Thailand;
Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin
   University of Colorado, Denver
      2018   Phase 3   NCT03347526   United States;
Cosyntropin Injectable Suspension, 1 mg/mL
   University of Colorado, Denver
      2018   Phase 3   NCT03347526   United States;
Decortin H
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom;
Fenfluramine
   University of California, Los Angeles
      2020   Phase 2   NCT04289467   United States;
GWP42003-P
   GW Research Ltd
      2017   Phase 3   NCT02954887   Poland;United States;
      2017   Phase 3   NCT02953548   Poland;United States;
      -   Phase 3   EUCTR2015-004904-50-PL   Hungary;Italy;Poland;United Kingdom;United States;
Ganaxolone
   Marinus Pharmaceuticals
      2007   Phase 2   NCT00442104   United States;
      2007   Phase 2   NCT00441896   United States;
   Marinus Pharmaceuticals, Inc.
      2007   -   EUCTR2006-004285-13-CZ   Czech Republic;
   Marinus Pharmceuticals, Inc.
      2007   -   EUCTR2006-004286-33-CZ   Czech Republic;
      -   Phase 2   EUCTR2006-004286-33-PL   Czech Republic;Poland;
Intravenous Methylprednisolone
   Suvasini Sharma
      2019   Phase 2/Phase 3   NCT03876444   India;
JBPOS0101
   Bio-Pharm Solutions Co., Ltd.
      2019   Phase 2   NCT03976076   United States;
Ketogenic diet
   All India Institute of Medical Sciences, New Delhi
      2022   Phase 2/Phase 3   NCT05279118   India;
M071754
   Alfresa Pharma Corporation
      2012   Phase 4   JPRN-JapicCTI-142559   -
      2012   Phase 3   JPRN-JapicCTI-142558   -
   Alfresa Pharma Corporation and Sanofi KK
      -   Phase 3   EUCTR2017-000611-17-Outside-EU/EEA   Japan;
      -   Phase 3   EUCTR2017-000230-62-Outside-EU/EEA   Japan;
Melatonin
   Department of Pediatrics, The First Medical Center, General Hospital of the People's Liberation Army of China
      2020   Phase 0   ChiCTR2000036208   China;
Modified Atkins diet
   All India Institute of Medical Sciences, New Delhi
      2009   Phase 2/Phase 3   NCT01006811   India;
Oral Pednisolone
   Suvasini Sharma
      2019   Phase 2/Phase 3   NCT03876444   India;
Oral prednisolone
   Lady Hardinge Medical College
      2012   Phase 3   NCT01575639   India;
Prednisolone
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom;
   The Hospital for Sick Children
      2017   Phase 3   NCT02299115   Canada;
Pyridoxine plus prednisolone
   Lady Hardinge Medical College
      2012   Phase 3   NCT01828437   India;
Radiprodil
   UCB Biopharma S.P.R.L.
      2017   Phase 2   NCT02829827   Belgium;Bulgaria;France;Germany;United Kingdom;
   UCB Biopharma SPRL
      2017   Phase 2   EUCTR2016-002107-26-FR   Belgium;Bulgaria;France;Germany;United Kingdom;
      2017   Phase 2   EUCTR2016-002107-26-DE   Belgium;Bulgaria;France;Germany;United Kingdom;
      2017   Phase 2   EUCTR2016-002107-26-BG   Belgium;Bulgaria;France;Germany;United Kingdom;
      2016   Phase 2   EUCTR2016-002107-26-GB   Belgium;Bulgaria;France;Germany;United Kingdom;
      2016   Phase 2   EUCTR2016-002107-26-BE   Belgium;Bulgaria;France;Germany;United Kingdom;
SABRIL SACHETS
   Royal United Hospital Bath NHS Trust
      2006   Phase 4   EUCTR2006-000788-27-GB   Germany;United Kingdom;
SOLUBLE PREDNISOLONE TABLETS
   Royal United Hospital Bath NHS Trust
      2006   Phase 4   EUCTR2006-000788-27-GB   Germany;United Kingdom;
SPT3162
   Marinus Pharmceuticals, Inc.
      2007   -   EUCTR2006-004286-33-CZ   Czech Republic;
      -   Phase 2   EUCTR2006-004286-33-PL   Czech Republic;Poland;
Sabril
   Amzell B.V.
      -   Phase 3   EUCTR2021-003015-26-FR   France;Germany;Poland;Spain;United States;
Sabril granules for oral use
   TARGEON
      -   Phase 2   EUCTR2014-000360-17-FR   France;
Sabrilex
   Kirsi Mikkonen/Helsinki University Hospital
      2018   Phase 4   EUCTR2017-004775-30-FI   Finland;
Sabril®
   Lundbeck LLC
      2009   -   NCT01073579   -
Synacthen Depot
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom;
Tetracosactide Acetate
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom;
      2006   Phase 4   EUCTR2006-000788-27-GB   Germany;United Kingdom;
Tricaprilin
   Cerecin
      2021   Phase 1   NCT04727970   Australia;Singapore;
UCB3491
   UCB Biopharma SPRL
      2017   Phase 2   EUCTR2016-002107-26-FR   Belgium;Bulgaria;France;Germany;United Kingdom;
      2017   Phase 2   EUCTR2016-002107-26-DE   Belgium;Bulgaria;France;Germany;United Kingdom;
      2017   Phase 2   EUCTR2016-002107-26-BG   Belgium;Bulgaria;France;Germany;United Kingdom;
      2016   Phase 2   EUCTR2016-002107-26-GB   Belgium;Bulgaria;France;Germany;United Kingdom;
      2016   Phase 2   EUCTR2016-002107-26-BE   Belgium;Bulgaria;France;Germany;United Kingdom;
VGB-ST soluble tablets
   TARGEON
      -   Phase 2   EUCTR2014-000360-17-FR   France;
Vigabatrin
   Alfresa Pharma Corporation
      2012   Phase 4   JPRN-JapicCTI-142559   -
      2012   Phase 3   JPRN-JapicCTI-142558   -
   Amzell B.V.
      -   Phase 3   EUCTR2021-003015-26-FR   France;Germany;Poland;Spain;United States;
   Benuvia Therapeutics Inc.
      2018   Phase 3   NCT03421496   United States;
   Lundbeck LLC
      2012   Phase 4   NCT01413711   -
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom;
      2006   Phase 4   EUCTR2006-000788-27-GB   Germany;United Kingdom;
   The Hospital for Sick Children
      2017   Phase 3   NCT02299115   Canada;
Vigabatrin Tablets
   Kullasate Sakpichaisakul
      2020   -   NCT04302116   Thailand;
Vigabatrin: Vigabatrin new ST formulation then Sabril®
   Orphelia Pharma
      2014   -   NCT02220114   France;
Vitamin B1
   Faculty of Pediatrics, the first Medical Centre, Chinese PLA General Hospital
      2021   Phase 0   ChiCTR2100045702   China;